This fact has also been reported in the treatment of ChS cells with 5-aza-2-deoxycitabine, which increased the expression of some CTAs, and yielded NY-ESO-1 and preferentially expressed antigen of melanoma (PRAME) specific CD8+ T cells to recognize and lyse ChS cell lines [165]. Here, CD8A is linked to melanoma.